We are live on ! Find out more
APTO

Aptose Biosciences, Inc.

Delisted

APTO was delisted on the 1st of April, 2025.

4 hedge funds and large institutions have $20.7K invested in Aptose Biosciences, Inc. in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% less funds holding

Funds holding: 164 (-12)

86% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 14

96% less capital invested

Capital invested by funds: $487K → $20.7K (-$466K)

Holders
4
Holders Change
-12
Holders Change %
-75%
% of All Funds
0.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
Closed
14
Calls
Puts
Net Calls
Net Calls Change

APTO Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q2 2025, worth a combined $20.7K — down 96% from $487K a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of APTO and 2 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was DRW Securities, opening a new position worth an estimated $33.8K. The largest seller was Bleichroeder LP, exiting entirely with an estimated $382K sold.

  • 4 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q2 2025, down from 16 in Q1 2025.
  • Funds reported $20.7K of Aptose Biosciences, Inc. stock for Q2 2025, down 96% quarter-over-quarter.
  • 2 funds opened new Aptose Biosciences, Inc. positions in Q2 2025 and 14 closed out, a net change of -12 holders.
  • The largest Aptose Biosciences, Inc. buyer in Q2 2025 was DRW Securities, an estimated $33.8K added.
  • The largest Aptose Biosciences, Inc. seller in Q2 2025 was Bleichroeder LP, an estimated $382K sold.

Based on aggregated 13F filings for Q2 2025.